EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Pharmigene's enterprise value is NT$1,244.7 Mil.
Pharmigene's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was NT$132.7 Mil. Therefore, Pharmigene's EV-to-Revenue for today is 9.38.
The historical rank and industry rank for Pharmigene's EV-to-Revenue or its related term are showing as below:
ROCO:7595'
s EV-to-Revenue Range Over the Past 10 Years
Min: 3 Med: 5.62 Max: 10.03
Current: 9.38
During the past 7 years, the highest EV-to-Revenue of Pharmigene was 10.03. The lowest was 3.00. And the median was 5.62.
ROCO:7595's EV-to-Revenue is ranked worse than 80.45% of 220
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.02
vs ROCO:7595: 9.38
As of today (2024-06-09), Pharmigene's stock price is NT$16.95.
Pharmigene's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was NT$2.90. Therefore, Pharmigene's PS Ratio for today is 5.85.
Pharmigene EV-to-Revenue Historical Data
The historical data trend for Pharmigene's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pharmigene's EV-to-Revenue
For the Diagnostics & Research subindustry, Pharmigene's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmigene's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pharmigene's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Pharmigene's EV-to-Revenue falls into.
Pharmigene's current Enterprise Value is NT$1,244.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pharmigene's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was NT$132.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmigene's share price for today is NT$16.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was NT$2.90.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmigene EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Pharmigene's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Pharmigene Inc is engaged in the development and sales of pharmaceutical genetic diagnostic products. Also, the company provides medical and drug testing services and equipment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:7595 has been successfully added to your 